Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,936 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting Not applicable Interventional

Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial

NCT05655936
View directory record Official record
Conditions
Preeclampsia, Hypertensive Disorder of Pregnancy, Toxemia, Pregnancy Complications, Hypertension, Pregnancy-Induced, Hypertension, Obesity, Overweight, Nutrition Disorders, Vascular Diseases, Cardiovascular Diseases, Pre-Eclampsia, Eclampsia, Gestational Hypertension
Interventions
Heart Health Doula Intervention Program, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Withdrawn No phase listed Observational

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

NCT00573092
View directory record Official record
Conditions
Myocardial Infarction, Cerebrovascular Accident, Death, Sudden, Cardiac
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting No phase listed Observational

Dilapan-S®: A Multicenter US E-registry

NCT04451109
View directory record Official record
Conditions
Post Term Pregnancy, Premature Rupture of Membrane, Fetal Growth Retardation, Oligohydramnios, Gestational Diabetes, High Blood Pressure in Pregnancy
Interventions
Dilapan-S
Device
Lead sponsor
Medicem Technology s.r.o.
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 28, 2026, 5:35 PM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Hypertension Remote Monitoring Evaluation Redesign

NCT06113458
View directory record Official record
Conditions
Hypertension
Interventions
Standard and One-time Training, Standard and Practice Facilitation, High-intensity and One-time Training, High-intensity and Practice Facilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

NCT07143448
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
HS235, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00465621
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Xalatan
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

NCT06153693
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
87
States / cities
Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT05516498
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional

The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants

NCT01915706
View directory record Official record
Conditions
Glaucoma
Interventions
Ripcord removal
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT06822738
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
XEN63 Glaucoma Treatment System
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Culver City, California • Petaluma, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional

eCulinary Medicine Emphasizing Herbs/Spices to Increase Vegetable Intake

NCT05587855
View directory record Official record
Conditions
Hypertension, Diet, Healthy, Culinary Medicine
Interventions
E-group
Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury

NCT07504055
View directory record Official record
Conditions
Spinal Cord Injury, Orthostatic Hypertension, Autonomic Dysreflexia
Interventions
Spinal Cord Transcutaneous Stimulation
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

NCT00006398
View directory record Official record
Conditions
Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions
Timolol Maleate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Xalacom, Xalatan, Timolol
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Community Based Treatment for (ComBaT) Glaucoma

NCT06124521
View directory record Official record
Conditions
Glaucoma
Interventions
ComBaT Glaucoma
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Community Models for Hypertension and Diabetes Care for Refugees

NCT04229667
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions
Improved Community Health Volunteer (CHV) program
Other
Lead sponsor
International Rescue Committee
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

NCT02914509
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies

NCT07659821
View directory record Official record
Conditions
Pregnant Women With Singleton Pregnancies
Interventions
Food Kit
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
3
States / cities
College Station, Texas • Dallas, Texas • Mansfield, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Repeated Far Infrared Sauna Bathing in Adults With Obesity

NCT07158047
View directory record Official record
Conditions
Obesity (Disorder)
Interventions
Heat therapy
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

2-HOBA in Systemic Lupus Erythematosus

NCT07225543
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 5:35 PM EDT